The place of central-acting drugs in the algorithms of treatment of primary obesity
https://doi.org/10.14341/omet2017218-23
Abstract
Pharmacotherapy is an essential component of obesity treatment, as well as efforts focused on changing the lifestyle, correcting the food consumption and increasing the physical activity. The administration of central-acting drugs as pharmacotherapy of obesity is pathogenetically justified and allows improving the effectiveness of treatment. In this article, the use of sibutramine, a serotonin and norepinephrine reuptake inhibitor, is considered in various aspects of endocrinologist’s practice. In addition to aforesaid there is an application of a specific clinical observation.
Supporting agencies: No
About the Authors
Oksana V. LogvinovaEndocrinology Research Centre
Russian Federation
post-graduate student of the department of therapeutic endocrinology
Competing Interests:
None disclosed
Marina O. Galieva
Endocrinology Research Centre
Russian Federation
post-graduate student of the department of therapeutic endocrinology
Competing Interests:
None disclosed
Natalia V. Mazurina
Endocrinology Research Centre
Russian Federation
PhD, leading researcher
Competing Interests:
None disclosed
Ekaterina A. Troshina
Endocrinology Research Centre
Russian Federation
MD, Prof., corresponding member of the RAS
Competing Interests:
None disclosed
References
1. Arroyo-Johnson C, Mincey KD. Obesity Epidemiology Worldwide. Gastroenterol Clin North Am. 2016;45(4):571-579. doi:10.1016/j.gtc.2016.07.012.
2. Wang W, Wei PL, Lee YC, et al. Short-term Results of Laparoscopic Mini-Gastric Bypass. Obes Surg. 2005;15(5):648-654. doi:10.1381/0960892053923752.
3. Ссылка на сайт: http://www.who.int/diabetes/country-profiles/rus_ru.pdf?ua=1
4. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017; 376(3):254-266. doi:10.1056/NEJMra1514009.
5. The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–154. doi:10.1056/NEJMoa1212914
6. Дедов И.И., Трошина Е.А., Мазурина Н.В., Логвинова О.В. Роль нейротрансмиттеров в регуляции энергетического гомеостаза и возможности медикаментозной коррекции его нарушений при ожирении // Ожирение и метаболизм. – 2016. – Т.13. – №1 – С.9-15. [Dedov II, Troshina EA, Mazurina NV, Logvinova OV. The role of neurotransmitters in regulation of energy homeostasis and possibility of drug correction of its disturbances in obesity. Obesity and metabolism. 2016;13(1):9-15. (In Russ).] doi: 10.14341/OMET201619-15.
7. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-62. doi: 10.1210/jc.2014-3415.
8. Бондаренко И.З., Бутрова С.А., Гончаров Н.П., и др. Лечение морбидного ожирения у взрослых. Национальные клинические рекомендации // Ожирение и метаболизм. – 2011. – Т. 8. – №3. – C. 75-83. doi: 10.14341/2071-8713-4844 [Bondarenko IZ, Butrova SA, Goncharov NP, et al. Lechenie morbidnogo ozhireniya u vzroslykhNatsional'nye klinicheskie rekomendatsii. Obesity and metabolism. 2011;8(3):75-83. (In Russ.)]
9. Yeo GS, Heisler LK. Unraveling the brain regulation of appetite: lessons from genetics. Nat Neurosci. 2012;15(10):1343–1349. doi: 10.1038/nn.3211.
10. Lam DD, Garfield AS, Marston OJ, et al. Brain serotonin system in the coordination of food intake and body weight. Pharmacol Biochem Behav. 2010;97(1): 84–91. doi: 10.1016/j.pbb.2010.09.003.
11. Mancini MC, de Melo ME. The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. Diabetol Metab Syndr. 2017;9(1):44. doi: 10.1186/s13098-017-0242-0.
12. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. doi: 10.1056/NEJMoa1411892
13. Трошина Е.А., Мазурина Н.В., Галиева М.О. Создание стратегий лечения ожирения и коморбидных заболеваний на основе наблюдательных программ: промежуточные результаты Всероссийской наблюдательной программы ПримаВера. // Альманах клинической медицины. – 2015. – №S1. – С. 95-101. [Troshina EA, Mazurina NV, Galieva MO. Development of therapeutic strategies for obesity and comorbid disorders based on observational programs: interim results of the Russian observational program PrimaVera. Almanah klinicheskoj mediciny. 2015; (S1): 95-101 (In Russ).].
14. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Стратегия управления ожирением: итоги Всероссийской наблюдательной программы «ПримаВера» // Ожирение и метаболизм. – 2016. – T. 13. – № 1. – С.36-44. [Dedov II, Mel'nichenko GA, Romantsova TI. The strategy of obesity management: the results of All-Russian observational program “Primavera”. Obesity and metabolism. 2016;13(1):36-44. (In Russ).] doi: 10.14341/omet2016136-44.
15. Douketis JD, Sharma AM. Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction. Semin Vasc Med. 2005;5(1):25–33. doi:10.1055/s-2005-871739
16. Bodary PF, Iglay HB, Eitzman DT. Strategies to reduce vascular risk associated with obesity. Curr Vasc Pharmacol. 2007;5(4):249–258. doi: 10.2174/157016107782023415
17. James WP, Caterson ID, Coutinho W, et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. N Engl J Med. 2010;363(10):905-917. doi: 10.1056/NEJMoa1003114.
18. Caterson ID, Finer N, Coutinho W, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012;14(6):523-530. doi: 10.1111/j.1463-1326.2011.01554.x.
19. Hayes JF, Bhaskaran K, Batterham R, et al. The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. Int J Obes (Lond). 2015;39(9):1359-1364. doi: 10.1038/ijo.2015.86.
Supplementary files
|
1. Неозаглавлен | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(132KB)
|
Indexing metadata ▾ | |
|
|
2. Рис. 1. Схема выбора терапии для лечения избыточной массы тела и первичного ожирения [7, 8]. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(99KB)
|
Indexing metadata ▾ | |
Review
For citations:
Logvinova O.V., Galieva M.O., Mazurina N.V., Troshina E.A. The place of central-acting drugs in the algorithms of treatment of primary obesity. Obesity and metabolism. 2017;14(2):18-23. (In Russ.) https://doi.org/10.14341/omet2017218-23
Views:
3898
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
